Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2000

View Archived Issues

La Jolla's lupus drug effective in patients with high-affinity antibodies

Cortex achieves first milestone in Organon agreement

Generex initiates long-term phase II trials of oral insulin formulation

Acadia and ArQule enter licensing agreement for lead serotonergic compounds

Vion expands TAPET trials, advances other products

SIB-1893 and other mGluR5 antagonists claimed for pain and anxiety

Fujisawa's new oxazole compounds particularly useful for glomerulonephritis

Chloride channel blockers as novel therapeutic approach to sickle cell disease and other disorders

Naphthalenecarboxamide-based tachykinin antagonists in development by AstraZeneca

Tanabe Seiyaku patents new inhibitors of PDE5

New lactones with anti-MRSA activity designed at Sankyo

Several new patents issued to Janssen for alpha2-adrenoceptor antagonists and their use

Memantine should be advanced to late-stage trials in PPN according to phase II results

Sepracor updates product development

TP-10 phase I/II study results presented at cardiovascular anesthesiology meeting

Nexell forms cell therapy and gene therapy alliance with Takara Shuzo

Ligand releases new data confirming Ontak's effectiveness in patients with severe psoriasis

Pregabalin phase I, phase II trials in painful peripheral neuropathy reported at AAN meeting

Therion's Prostvac vaccine shows promise in phase I prostate cancer study

United Therapeutics to begin Flolan-to-Uniprost transition study

AU-461 headed for development as a novel therapeutic agent for peptic ulcer

Medarex highlights Q1 developments marked by continued partnership arrangements

Pharmacological profile of SL-650472, a novel antiplatelet, antithrombotic agent

Elan completes acquisition of The Liposome Company

HCT-1026 enters phase II trials for overactive bladder

CNS-5161 being rapidly advanced to phase II for pain; development partner will be sought

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...